Brief: Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse for Advanced Parkinson’s Disease
15/05/2024 12:37
May 15 (Reuters) - Serina Therapeutics Inc SER.A :
* ENABLE INJECTIONS AND SERINA THERAPEUTICS ANNOUNCE
AGREEMENT TO
DEVELOP SER-252 IN COMBINATION WITH ENFUSE® FOR ADVANCED
PARKINSON’S DISEASE
* SERINA THERAPEUTICS INC - PLANS TO ADVANCE SER-252 TO
CLINICAL
TESTING IN 2025
* SERINA THERAPEUTICS INC: WILL OBTAIN A WORLDWIDE,
EXCLUSIVE
LICENSE TO ENFUSE PLATFORM FOR AN UPFRONT AND FUTURE MILESTONE
PAYMENTS
* SERINA THERAPEUTICS INC: ENABLE WILL ALSO BE ENTITLED TO
PRODUCT
SALES AND SINGLE DIGIT ROYALTIES.
Source text for Eikon: ID:nGNX3rsKVR
Further company coverage: SER.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Serina Therapeutics
See all newsBrief: Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2
Brief: Serina Therapeutics - Offers Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments - SEC Filing
Serina Therapeutics Q2 net loss widens on higher expenses
Brief: Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors
Brief: Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252